Sarepta Therapeutics (SRPT) Offering Seeing High Demand, Expected to Price at Modest Discount - Feurstein

September 22, 2016 3:40 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) offering well oversubscribed, upsized and seen pricing at a modest discount to close. - Adam Feurstein.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Rumors, Trader Talk

Related Entities

Adam Feuerstein

Add Your Comment